Investigational anti-diabetic may offer potential for management of non-alcoholic fatty liver

Data presented today at The International Liver Congress™ 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. —> Read More